Gregor Wollensak1, Eberhard Spoerl. 1. Department of Ophthalmology, Technical University of Dresden, Dresden, Germany. gwollens@hotmail.com
Abstract
PURPOSE: To develop methods of collagen crosslinking the sclera to increase its biomechanical strength for the treatment of progressive myopia. SETTING: Department of Ophthalmology, Technical University of Dresden, Dresden, Germany. METHODS: Sagitally oriented scleral strips of 4.0 mm x 8.0 mm were prepared from 5 human postmortem eyes and 50 porcine cadaver eyes and treated with various crosslinking methods including physical crosslinking by combined riboflavin-ultraviolet A (UVA) or rose bengal/white-light irradiation and chemical crosslinking by incubation with glucose, ribose, glyceraldehyde, and glutaraldehyde solutions. Parallel scleral strips from the same eye were used as untreated controls. After crosslinking, stress-strain measurements of the treated and control scleras were performed using a microcomputer-controlled biomaterial tester. RESULTS: A statistically significant increase in scleral rigidity was found after crosslinking with riboflavin-UVA, with a rise in stress in treated porcine (157%) and human (29%) sclera, and after treatment with glyceraldehyde, with a rise in stress in treated porcine (487%) and human (34%) sclera, and with glutaraldehyde, with a rise in stress in treated porcine (817%) and human sclera (122%) at 8% strain. The other crosslinking methods proved ineffective. The untreated human sclera had a 4-fold higher stiffness than porcine sclera. CONCLUSIONS: Collagen crosslinking induced by riboflavin-UVA, glyceraldehyde, and glutaraldehyde led to a significant increase in biomechanical strength in human and porcine sclera. Using these methods, collagen crosslinking might become a treatment possibility for progressive myopia. Future animal and clinical studies must determine the best application methods and the long-term effects of increased crosslinking on scleral rigidity and prevent potential toxicity or serious side effects.
PURPOSE: To develop methods of collagen crosslinking the sclera to increase its biomechanical strength for the treatment of progressive myopia. SETTING: Department of Ophthalmology, Technical University of Dresden, Dresden, Germany. METHODS: Sagitally oriented scleral strips of 4.0 mm x 8.0 mm were prepared from 5 human postmortem eyes and 50 porcine cadaver eyes and treated with various crosslinking methods including physical crosslinking by combined riboflavin-ultraviolet A (UVA) or rose bengal/white-light irradiation and chemical crosslinking by incubation with glucose, ribose, glyceraldehyde, and glutaraldehyde solutions. Parallel scleral strips from the same eye were used as untreated controls. After crosslinking, stress-strain measurements of the treated and control scleras were performed using a microcomputer-controlled biomaterial tester. RESULTS: A statistically significant increase in scleral rigidity was found after crosslinking with riboflavin-UVA, with a rise in stress in treated porcine (157%) and human (29%) sclera, and after treatment with glyceraldehyde, with a rise in stress in treated porcine (487%) and human (34%) sclera, and with glutaraldehyde, with a rise in stress in treated porcine (817%) and human sclera (122%) at 8% strain. The other crosslinking methods proved ineffective. The untreated human sclera had a 4-fold higher stiffness than porcine sclera. CONCLUSIONS: Collagen crosslinking induced by riboflavin-UVA, glyceraldehyde, and glutaraldehyde led to a significant increase in biomechanical strength in human and porcine sclera. Using these methods, collagen crosslinking might become a treatment possibility for progressive myopia. Future animal and clinical studies must determine the best application methods and the long-term effects of increased crosslinking on scleral rigidity and prevent potential toxicity or serious side effects.
Authors: Michaël J A Girard; J-K Francis Suh; Michael Bottlang; Claude F Burgoyne; J Crawford Downs Journal: Invest Ophthalmol Vis Sci Date: 2011-07-29 Impact factor: 4.799
Authors: Natasha Babar; MiJung Kim; Kerry Cao; Yukari Shimizu; Su-Young Kim; Anna Takaoka; Stephen L Trokel; David C Paik Journal: Invest Ophthalmol Vis Sci Date: 2015-01-29 Impact factor: 4.799
Authors: Keyton Clayson; Xueliang Pan; Elias Pavlatos; Ryan Short; Hugh Morris; Richard T Hart; Jun Liu Journal: Exp Eye Res Date: 2017-08-30 Impact factor: 3.467
Authors: Michaël J A Girard; J-K Francis Suh; Michael Bottlang; Claude F Burgoyne; J Crawford Downs Journal: Invest Ophthalmol Vis Sci Date: 2009-06-03 Impact factor: 4.799